Neuroscience

Parkinson's disease
#Financing #Mission Therapeutics #Parkinson's

Mission Therapeutics raises $13.3 million for Parkinson’s treatment

Biotech company Mission Therapeutics has raised $13.3 million to progress the clinical development of its lead candidate for the treatment of Parkinson’s disease.  The lead candidate MTX35 works by inhibiting USP30, a mitochondrial de-ubiquitylating enzyme (DUB), increasing mitochondrial ubiquitylation and promoting appropriate mitophagy. This is the essential… Read More

#Business & Investment #News

Human brain
#Biomarkers #Drug discovery #Neurology #Neuroscience #Whitepaper

Navigating neurological biomarker research: Download the Whitepaper

Neurological biomarker research is advancing rapidly, but key challenges remain. Download this new Whitepaper from Olink entitled ‘Navigating neurological biomarker research: Progress, learnings and future directions’. The Whitepaper captures: Expert perspectives from academia and biopharma Highlighting successes, setbacks, and strategies for translational advancements in Alzheimer’s, Parkinson’s, and MS. A… Read More

#News

#Biomarkers #Drug discovery #Neurology #Neuroscience #Whitepaper

Navigating neurological biomarker research: Progress, learnings and future directions

Neurological biomarker research is advancing rapidly, but key challenges remain. This Whitepaper captures: Expert perspectives from academia and biopharma Highlighting successes, setbacks, and strategies for translational advancements in Alzheimer’s, Parkinson’s, and MS. A must-read for researchers navigating the future of precision neurology. Read More

#Resources #Whitepapers

Neuroscience innovation
#Ageing #Mass spectrometry / NMR #Neuroscience #Protein chemistry / Proteomics #Proteomics

Deciphering proteome alterations in neurodegeneration with mass spectrometry 

Daniel Hornburg PhD, Vice-President Biomarkers & Precision Medicine, Bruker Daltonics, Stefan Foser, Vice President Global Pharma, Bruker Daltonics, and Torsten Müller, Business Development Manager, Proteomics, Bruker Daltonics, explore how MS-based proteomics can be used to dissect disease biology with spatial resolution.   Impact of neurodegeneration for ageing societies… Read More

#Exclusive Content

Neuroscience Parkinson's disease
#Parkinson's

Positive results announced for Parkinson’s treatment ARV-102  

Biotechnology company Arvinas has announced positive results for its Phase I clinical trial of ARV-102 in Parkinson’s disease.  The results, presented at the International Congress of Parkinson’s Disease and Movement Disorders in Honolulu, show positive pharmacokinetic, pharmacodynamic, and biomarker data from two Phase I clinical trials evaluating… Read More

#News

Neuron
#Gain Therapeutics #Neurodegenerative disorders #Neuroscience #Parkinson's #Phase I trial

Early data suggest GT-02287 slows Parkinson’s disease

Gain Therapeutics has shared early safety and tolerability findings, the primary endpoint, and observations from key exploratory endpoints from the Phase Ib clinical study of GT-02287 in people with Parkinson’s disease (PD) with or without a GBA1 mutation.  The findings were presented in a poster at the… Read More

#News #Trending News

#Neuroscience

Whitepaper – Navigating Neurological Biomarker Research: Progress, Learnings and Future Directions

Neurological biomarker research is advancing rapidly, but key challenges remain. This whitepaper captures: Expert perspectives from academia and biopharma Highlighting successes, setbacks, and strategies for translational advancements in Alzheimer’s, Parkinson’s, and MS. A must-read for researchers navigating the future of precision neurology.   Brought to… Read More

#Whitepapers

#Blood-based biomarkers #Neurodegenerative disorders #Neuroscience #Proteomics

How blood proteomics is accelerating neuro drug discovery

This article is sponsored by Standard BioTools. Neurodegenerative diseases affect more than 57 million people globally, a figure expected to double within two decades1,2. This alarming projection reflects three major clinical challenges: difficulty diagnosing disease in early, treatable stages; a lack of curative therapies; and limited treatment options2,3. Read More

#Exclusive Content

Drugs targeting amyloid Plaque
#Alzheimer's #Eli Lilly #European Commission #Neurodegenerative disorders #Neuroscience

European Commission extends EU use of Lilly’s donanemab

The European Commission (EC) has granted marketing authorisation for Lilly’s Kisunla (donanemab) in early symptomatic Alzheimer’s disease (AD).  It is approved in adults with mild cognitive impairment as well as those with mild dementia stages of AD with confirmed amyloid pathology who are apolipoprotein E (ApoE4) heterozygotes… Read More

#News #Regulatory

#Drug discovery #Funding #Neuroscience #Parkinson's #The Michael J Fox Foundation for Parkinson’s Research (MJFF)

Lys Therapeutics awarded $5m to advance neuro pipeline  

French biotech Lys Therapeutics has received a grant award of $5 million (£3.6 million) from The Michael J Fox Foundation for Parkinson’s Research (MJFF) to accelerate the clinical development of its first-in-class monoclonal antibody for the treatment of Parkinson’s disease and other neurodegenerative disorders.  The funding… Read More

#News

#Clinical trial #Drug discovery #Gene therapy #Neuroscience #Parkinson's

AskBio begins second phase of gene therapy trial for Parkinson’s  

The first European patients have been randomised in a Phase II gene therapy clinical trial for Parkinson’s disease (PD), AskBio has announced.   The REGENERATE-PD clinical trial is evaluating the safety and efficacy of AskBio’s investigational gene therapy AB-1005 and will enrol approximately 87 patients across clinical trial… Read More

#Editor's Choice #News

#Alzheimer's #Dementia #Neurodegenerative disorders #Neuroscience

What’s next for dementia drug research and development? 

To mark World Alzheimer’s Day on 21 September, Drug Discovery World speaks to biotech companies and investors at the forefront of next-generation dementia drugs.  After years of trudging through something akin to a Slough of Despond, dementia researchers, clinicians and patients have finally been given something to… Read More

#Exclusive Content

#Cell and gene therapy #Drug discovery #Mental health #National Institute for Health and Care Excellence (NICE)

This week in drug discovery 8-12 September

News round-up for 8-12 September by DDW Editor Reece Armstrong. Fast-track designations by the FDA, clinical trials to advance mental health and pharma team-ups to bring innovations to market are just some of the stories in this week’s news round-up. The top stories FDA fast-tracks Sanofi’s AMD gene therapy… Read More

#News

Patient speaking to psychiatrist
#Clinical trials #Mental health #Psychiatry #UK

First NHS-embedded clinical trial site for mental health launches

The UK’s first fully NHS-embedded commercial research for brain and mental health conditions has been launched by Clerkenwell Health.   Developed in partnership with Rotherham Doncaster and South Humber (RDaSH) NHS Foundation Trust, the initiative aims to set a new standard for how trials are delivered in the… Read More

#News

MHRA
#Biogen #Clinical trials #Mental health #MHRA #Regulatory #UK

Treatment for post-natal depression authorised in UK

The first targeted treatment for post-natal depression (PND) has been authorised for use in the UK through the approval of Biogen’s zuranolone by the Medicines and Healthcare Products Regulatory Agency (MHRA). Biogen state that the marketing authorisation by the MHRA addresses a critical, unmet need in maternal health due to… Read More

#News